The estimated Net Worth of Stephanie Okey is at least $1.85 Миллион dollars as of 28 March 2024. Ms. Okey owns over 17,500 units of Crinetics Pharmaceuticals Inc stock worth over $1,192,390 and over the last 6 years she sold CRNX stock worth over $227,570. In addition, she makes $429,791 as Independent Director at Crinetics Pharmaceuticals Inc.
Sign up
Ms. Okey CRNX stock SEC Form 4 insiders trading
Stephanie has made over 4 trades of the Crinetics Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 17,500 units of CRNX stock worth $320,075 on 28 March 2024.
The largest trade she's ever made was exercising 17,500 units of Crinetics Pharmaceuticals Inc stock on 28 March 2024 worth over $320,075. On average, Stephanie trades about 851 units every 46 days since 2018. As of 28 March 2024 she still owns at least 23,500 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Ms. Okey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephanie Okey biography
Stephanie S. Okey serves as Independent Director of the Company. Ms. Okey served in various positions of increasing responsibility in the biopharmaceutical industry, first at Genentech, Inc., followed by 19 years at Genyzme, a Sanofi company. Ms. Okey’s management experience during her tenure at Genyzme included serving as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases from August 2012 to July 2015 and as Vice President and General Manager, U.S. Genetic Diseases Business Unit from September 2011 to August 2012. Ms. Okey retired from Genzyme in July 2015. Since June 2018, Ms. Okey has served as a member of the board of directors of Albireo Pharma, Inc., a Nasdaq-listed biopharmaceutical company and since December 2018, Ms. Okey has served as a member of the board of directors of PTC Therapeutics, a Nasdaq-listed biopharmaceutical company. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey received a B.S. degree in Zoology from The Ohio State University and a M.S. degree in Immunology and Medical Microbiology from Wright State University. Ms. Okey’s executive leadership experience in the life science industry and service on various biopharmaceutical company boards contributed to our board of directors’ conclusion that she should serve as a director of our company.
What is the salary of Stephanie Okey?
As the Independent Director of Crinetics Pharmaceuticals Inc, the total compensation of Stephanie Okey at Crinetics Pharmaceuticals Inc is $429,791. There are 6 executives at Crinetics Pharmaceuticals Inc getting paid more, with R. Scott Struthers having the highest compensation of $3,766,660.
How old is Stephanie Okey?
Stephanie Okey is 60, she's been the Independent Director of Crinetics Pharmaceuticals Inc since 2019. There are 2 older and 16 younger executives at Crinetics Pharmaceuticals Inc. The oldest executive at Crinetics Pharmaceuticals Inc is Wendall Wierenga, 72, who is the Independent Chairman of the Board.
What's Stephanie Okey's mailing address?
Stephanie's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.
Insiders trading at Crinetics Pharmaceuticals Inc
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen и Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
What does Crinetics Pharmaceuticals Inc do?
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
What does Crinetics Pharmaceuticals Inc's logo look like?
Complete history of Ms. Okey stock trades at Albireo Pharma Inc, PTC Therapeutics Inc, Catalent и Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc executives and stock owners
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
R. Scott Struthers,
President, Chief Executive Officer, Director -
Alan Krasner,
Chief Medical Officer -
Marc Wilson,
Chief Financial Officer -
Dr. R. Scott Struthers Ph.D.,
Founder, Pres, CEO & Director -
Dr. Ajay Madan DABT, Ph.D., D.A.B.T.,
Chief Devel. Officer -
Marc J. C. Wilson,
CFO & Sec. -
Stephanie Okey,
Independent Director -
Wendall Wierenga,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
Jeff E. Knight,
Chief Operating Officer -
Stephen Kaldor,
Independent Director -
Weston Nichols,
Independent Director -
Peter Trainer,
Vice President - Clinical Endocrinology -
Camille Bedrosian,
Independent Director -
Adriana Cabre,
Vice President of Human Resources -
Ajay Madan,
Chief Development Officer -
Chris Robillard M.B.A.,
Chief Bus. Officer -
James Hassard,
Chief Commercial Officer -
Dr. Alan S. Krasner M.D.,
Chief Medical Officer -
Adriana Cabre M.B.A.,
Chief HR Officer -
Kevin Capps,
Head of Intellectual Property -
Dr. Alan S. Krasner,
Chief Medical Officer -
Garlan Adams,
Gen. Counsel -
Dr. Stephen F. Betz Ph.D.,
Founder & Chief Scientific Officer -
Dr. Yun-Fei Zhu,
Founder & VP of Chemistry -
Jeff E. Knight,
Chief Operating Officer -
Advisors Llcperceptive Life...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
James Hassard,
Chief Commercial Officer -
Jack Nielsen,
Director -
Coelho Rogerio Vivaldi,
-
Dana Pizzuti,
Chief Med and Dev Officer -
Stephen F. Betz,
Chief Scientific Officer -
Caren Deardorf,